Q1 Earnings Estimate for Belite Bio Issued By HC Wainwright

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) – Stock analysts at HC Wainwright lifted their Q1 2026 earnings per share (EPS) estimates for shares of Belite Bio in a research report issued to clients and investors on Monday, April 13th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of ($0.70) per share for the quarter, up from their previous forecast of ($0.71). HC Wainwright has a “Buy” rating and a $200.00 price objective on the stock. The consensus estimate for Belite Bio’s current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Belite Bio’s Q3 2026 earnings at ($0.75) EPS.

Belite Bio (NASDAQ:BLTE) last posted its quarterly earnings data on Monday, March 2nd. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.18.

A number of other research analysts also recently weighed in on BLTE. Weiss Ratings reiterated a “sell (d-)” rating on shares of Belite Bio in a report on Tuesday, April 7th. Wall Street Zen upgraded Belite Bio from a “sell” rating to a “hold” rating in a research report on Saturday, April 4th. Cantor Fitzgerald lifted their target price on Belite Bio from $200.00 to $266.00 and gave the company an “overweight” rating in a research note on Tuesday, March 3rd. Morgan Stanley upped their target price on Belite Bio from $191.00 to $201.00 and gave the company an “overweight” rating in a report on Tuesday, March 3rd. Finally, Needham & Company LLC set a $217.00 price target on shares of Belite Bio in a research report on Tuesday, March 3rd. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Belite Bio presently has an average rating of “Moderate Buy” and a consensus target price of $202.33.

Belite Bio Stock Down 1.8%

Shares of NASDAQ:BLTE opened at $168.76 on Wednesday. The company’s fifty day moving average is $171.45 and its two-hundred day moving average is $144.43. The company has a market cap of $6.74 billion, a P/E ratio of -73.37 and a beta of -1.22. Belite Bio has a 12-month low of $53.60 and a 12-month high of $200.00.

Institutional Investors Weigh In On Belite Bio

Institutional investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd increased its holdings in Belite Bio by 28,200.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 283 shares of the company’s stock worth $45,000 after buying an additional 282 shares during the last quarter. Bank of America Corp DE lifted its stake in Belite Bio by 28.1% in the third quarter. Bank of America Corp DE now owns 1,171 shares of the company’s stock valued at $87,000 after acquiring an additional 257 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Belite Bio in the fourth quarter valued at approximately $103,000. Persistent Asset Partners Ltd bought a new stake in Belite Bio in the fourth quarter worth approximately $108,000. Finally, GAMMA Investing LLC grew its position in Belite Bio by 11.1% in the third quarter. GAMMA Investing LLC now owns 1,758 shares of the company’s stock worth $130,000 after acquiring an additional 176 shares in the last quarter. 0.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Belite Bio

In other Belite Bio news, CFO Hao-Yuan Chuang sold 6,200 shares of the business’s stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $181.50, for a total value of $1,125,300.00. Following the transaction, the chief financial officer owned 93,800 shares in the company, valued at $17,024,700. The trade was a 6.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Yu-Hsin Lin sold 9,200 shares of the company’s stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $181.45, for a total value of $1,669,340.00. Following the completion of the transaction, the chief executive officer directly owned 170,934 shares in the company, valued at approximately $31,015,974.30. The trade was a 5.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 16,500 shares of company stock valued at $2,993,113. 13.29% of the stock is owned by insiders.

Key Headlines Impacting Belite Bio

Here are the key news stories impacting Belite Bio this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and a $200 price target on BLTE, signaling continued analyst confidence despite forecast changes. HC Wainwright Reaffirms “Buy”
• Positive Sentiment: Belite reported an upside surprise on its March quarter results (EPS beat), which supports investor optimism around the business beat-and-build narrative. BLTE MarketBeat Profile
• Neutral Sentiment: HC Wainwright made a very small upward tweak to its Q1‑2026 EPS estimate (from -$0.71 to -$0.70), a data point that is unlikely to materially move the stock on its own. Analyst Note
• Neutral Sentiment: Institutional ownership remains very low (reported ~0.53%), and recent small institutional buys/sells are unlikely to drive major flows. Institutional Trading Details
• Neutral Sentiment: Analyst coverage is mixed: several buy/overweight targets above $200 offset a few hold/sell views — consensus remains a “Moderate Buy” with an average target ~ $202. Analyst Consensus
• Negative Sentiment: HC Wainwright cut its Q3, Q4 and FY‑2026 EPS forecasts (Q3 and Q4 revised down; FY2026 lowered from $1.89 to $1.62), which reduces near‑term earnings expectations and can pressure the stock. Analyst Estimate Cuts
• Negative Sentiment: Director Wan‑Shan Chen sold 1,100 shares (~$180 avg price) in early April; insider selling can be interpreted negatively by the market. Director Sale
• Negative Sentiment: Another insider, Hao‑Yuan Chuang, sold 6,200 shares — additional insider sales add to downward pressure on sentiment. Insider Sale by Hao‑Yuan Chuang
• Neutral Sentiment: Coverage pieces asking when Belite will be profitable provide context but no new catalyst; they may keep focus on timing of clinical progress and path to profitability. When Can We Expect A Profit?

Belite Bio Company Profile

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.